Holen Sie sich die Stockscreener-App
14.94
0.20%
0.03
Vorhandelsmarkt:
14.90
-0.04
-0.27%
Schlusskurs vom Vortag:
$14.91
Offen:
$15.03
24-Stunden-Volumen:
749.05K
Relative Volume:
0.57
Marktkapitalisierung:
$755.16M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-156.39M
KGV:
-4.0488
EPS:
-3.69
Netto-Cashflow:
$-123.06M
1W Leistung:
-2.42%
1M Leistung:
-1.52%
6M Leistung:
+2.47%
1J Leistung:
+70.35%
1-Tages-Spanne:
$14.61
$15.13
1-Wochen-Bereich:
$14.61
$16.65
52-Wochen-Spanne:
$8.50
$19.00
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Firmenname
Kalvista Pharmaceuticals Inc
Sektor
Branche
Telefon
(857) 999-0075
Adresse
200 CROSSING BOULEVARD, FRAMINGHAM, MA
Vergleichen Sie KALV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
14.94 | 753.65M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-09 | Bestätigt | Needham | Buy |
| 2026-01-06 | Bestätigt | Needham | Buy |
| 2025-01-31 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2025-01-07 | Eingeleitet | TD Cowen | Buy |
| 2024-12-18 | Eingeleitet | BofA Securities | Buy |
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-29 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-20 | Eingeleitet | Needham | Buy |
| 2018-10-30 | Eingeleitet | Jefferies | Buy |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-08-31 | Eingeleitet | BTIG Research | Buy |
Alle ansehen
Kalvista Pharmaceuticals Inc Aktie (KALV) Neueste Nachrichten
KalVista’s Pediatric HAE Trial for Sebetralstat Reaches Completion, Setting Up a Key Catalyst for KALV - TipRanks
Does KalVista Pharmaceuticals (KALV) have the potential to rally 117.98% as Wall Street analysts expect? - MSN
Understanding the Setup: (KALV) and Scalable Risk - Stock Traders Daily
Emerald Mutual Fund Advisers Trust Grows Stake in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
KalVista Pharmaceuticals (KALV) Stock Analysis: Exploring The 100% Upside Potential - DirectorsTalk Interviews
Emerald Advisers LLC Grows Position in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Hereditary Angioedema Market Poised for Strong Growth, Valued - openPR.com
Hereditary Angioedema Market Poised for Strong Growth, Valued at ~USD 3 Billion in 2023 and Set to Expand Through 2034: DelveInsight - Barchart.com
Multicare and KalVista collaboration in Latin America - The Pharma Letter
Multicare, KalVista to expand oral HAE treatment in Latin America - Mexico Business News
Aug Macro: What analysts say about KalVista Pharmaceuticals Inc stockQuarterly Market Review & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Recap Report: What chart patterns are forming on KalVista Pharmaceuticals IncWeekly Profit Recap & Detailed Earnings Play Strategies - baoquankhu1.vn
Can KalVista Pharmaceuticals Inc withstand a market correction2025 Sector Review & Breakout Confirmation Alerts - baoquankhu1.vn
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Published on: 2026-01-16 10:42:21 - baoquankhu1.vn
Aug Weekly: Can Zoetis Inc sustain its profitabilityOptions Play & Technical Entry and Exit Tips - baoquankhu1.vn
Does KalVista Pharmaceuticals (KALV) Have the Potential to Rally 117.98% as Wall Street Analysts Expect? - sharewise.com
Can KalVista Pharmaceuticals Inc stock sustain revenue growthQuarterly Earnings Report & Long-Term Growth Plans - Bộ Nội Vụ
KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Down 7.2%Time to Sell? - MarketBeat
KalVista reports $49M in 2025 Ekterly revenue, shares rise - MSN
HAE treatment Ekterly hits $49M sales in months since July launch - Angioedema News
The Technical Signals Behind (KALV) That Institutions Follow - Stock Traders Daily
Analysts Expect Breakeven For KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Before Long - 富途资讯
What is HC Wainwright's Forecast for KALV FY2030 Earnings? - MarketBeat
Health Check: How Prudently Does KalVista Pharmaceuticals (NASDAQ:KALV) Use Debt? - simplywall.st
Kalvista Stock Surges On Strong EKTERLY Uptake - Nasdaq
KalVista Pharmaceuticals (NASDAQ:KALV) Hits New 52-Week High Following Analyst Upgrade - MarketBeat
KalVista Details Early Sales, Prescriber Uptake For Newly Approved Rare Swelling Drug - Benzinga
Kalvista stock surges as Stifel reiterates Buy on strong Ekterly sales By Investing.com - Investing.com South Africa
Kalvista stock surges as Stifel reiterates Buy on strong Ekterly sales - Investing.com Nigeria
Stock Market Today: Dow, Nasdaq 100 And S&P 500 Futures Gain After December Jobs Data— General Motors, Tilray In Focus (UPDATED) - Benzinga
Needham raises Kalvista Pharmaceuticals stock price target on strong Ekterly sales - Investing.com Australia
Needham raises Kalvista Pharmaceuticals stock price target on strong Ekterly sales By Investing.com - Investing.com South Africa
KalVista Pharmaceuticals (KALV) Receives Buy Rating with Increas - GuruFocus
Kalvista stock price target raised to $29 from $28 at Citizens on strong Ekterly launch - Investing.com Australia
KALV: Needham Raises Price Target to $35, Maintains Buy Rating | - GuruFocus
Kalvista stock price target raised to $29 from $28 at Citizens on strong Ekterly launch By Investing.com - Investing.com South Africa
KalVista Stock Pre-Market (+14%) : Reports Strong EKTERLY Launch Revenue - Trefis
KalVista Pharmaceuticals stock rallies after hours on strong genetic disorder drug sales kickstart - MSN
KalVista Pharmaceuticals Stock Rallies After Hours On Strong Genetic Disorder Drug Sales Kickstart - Stocktwits
KalVista stock soars after strong Q4 revenue for oral HAE treatment EKTERLY By Investing.com - Investing.com South Africa
KalVista reports $35 million Q4 revenue for oral HAE treatment EKTERLY By Investing.com - Investing.com South Africa
KalVista stock soars after strong Q4 revenue for oral HAE treatment EKTERLY - Investing.com Nigeria
KalVista reports $35 million Q4 revenue for oral HAE treatment EKTERLY - Investing.com
Finanzdaten der Kalvista Pharmaceuticals Inc-Aktie (KALV)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):